Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2426330 | 1.00 | GAA (0.42) | GAAMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL810416 | 1.00 | GAA (0.42) | GAAMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL810193 | 0.86 | GAA (0.39) | GAAMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL810192 | 0.86 | GAA (0.39) | GAAMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL811198 | 0.80 | GAA (0.45) | GAAMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL811197 | 0.80 | GAA (0.45) | GAAMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL810637 | 0.78 | GAA (0.43) | GAAMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL810636 | 0.78 | GAA (0.43) | GAAMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL811210 | 0.77 | GAA (0.42) | GAAMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL811211 | 0.77 | GAA (0.42) | GAAMAPTALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367824-B1 | Anti-viral derivatives of pyrimidine | ABBVIE INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9163017-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-8546405-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-10-01 | — | — | US | disclosed |
| US-8541424-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-09-24 | — | — | US | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-2367823-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2367824-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| WO-2010075376-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075380-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100160355-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | GAA 504/4885MAPT 1347/4885ALDH1A1 2723/4885 |
| US-20100168138-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | GAA 223/4885MAPT 2833/4885ALDH1A1 2858/4885 |
| US-20100160355-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | GAA 223/4885MAPT 2833/4885ALDH1A1 2858/4885 |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | GAA 504/4885MAPT 1347/4885ALDH1A1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.